Gilead has launched Atripla, the first once-daily oral treatment for adults with HIV-1 infection.

Each tablet contains a fixed-dose combination of three existing HIV medicines — efavirenz 600mg, emtricitabine 200mg and tenofovir disoproxil (as fumarate) 245mg.

Treatment is indicated in adults with virologic suppression to HIV-1 RNA levels of <50 copies/ml on combination antiretroviral therapy for more than three months. The dose of Atripla is one tablet taken daily on an empty stomach, preferably at bedtime.

Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components in Atripla prior to initiation of their first antiretroviral treatment regimen.

Studies have shown that patients can be switched from other regimens to Atripla while maintaining viral suppression and prolonging efficacy.

View Atripla drug record

Further information: Gilead

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more